Hypertrophic cardiomyopathy - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Hypertrophic cardiomyopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hypertrophic cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hypertrophic cardiomyopathy: Overview
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick (hypertrophied). The thickened heart muscle can make it harder for the heart to pump blood. Signs and symptoms of HCM include: Chest pain, especially with physical exertion, Shortness of breath, especially with physical exertion, Fatigue, Arrhythmias (abnormal heart rhythms), Dizziness, Lightheadedness, Fainting (syncope), swelling in the ankles, feet, legs, abdomen and veins in the neck.
Hypertrophic cardiomyopathy is most often inherited. HCM is the most common form of genetic heart disease. It can happen at any age, but most receive a diagnosis in middle age. HCM is diagnosed based on medical history, family history, a physical exam and diagnostic test results.
Medications called beta-blockers, calcium channel blockers and diuretics offer limited and varying relief of symptoms. They may help with function but may also have adverse side effects. A range of surgical and nonsurgical procedures can be used to treat HCM: Septal myectomy- Septal myectomy is open-heart surgery. Alcohol septal ablation (nonsurgical procedure) - In this procedure, ethanol (a type of alcohol) is injected through a tube into the small artery that supplies blood to the area of heart muscle thickened by HCM. Surgically implanted devices – Surgeons can implant several types of devices to help the heart work better, including: Implantable cardioverter defibrillator (ICD), Pacemaker, Cardiac resynchronization therapy (CRT) device. Heart transplant – In HCM patients with advanced, end-stage disease, a heart transplant may be considered. In this procedure, a person’s diseased heart is replaced with a healthy donor heart.
Report Highlights
This segment of the Hypertrophic cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertrophic cardiomyopathy Emerging Drugs
In May, 2021, Bristol Myers Squibb announced that data from multiple studies across the company’s clinical program investigating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) will be presented at the upcoming American College of Cardiology’s 70th Annual Scientific Session (ACC.21).
It is currently in Phase II stage of development for Hypertrophic cardiomyopathy and is being developed by Imbria pharmaceticals.
Further product details are provided in the report..
Hypertrophic cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Hypertrophic cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
Hypertrophic cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypertrophic cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertrophic cardiomyopathy drugs.
Hypertrophic cardiomyopathy Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Hypertrophic cardiomyopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hypertrophic cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hypertrophic cardiomyopathy: Overview
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick (hypertrophied). The thickened heart muscle can make it harder for the heart to pump blood. Signs and symptoms of HCM include: Chest pain, especially with physical exertion, Shortness of breath, especially with physical exertion, Fatigue, Arrhythmias (abnormal heart rhythms), Dizziness, Lightheadedness, Fainting (syncope), swelling in the ankles, feet, legs, abdomen and veins in the neck.
Hypertrophic cardiomyopathy is most often inherited. HCM is the most common form of genetic heart disease. It can happen at any age, but most receive a diagnosis in middle age. HCM is diagnosed based on medical history, family history, a physical exam and diagnostic test results.
Medications called beta-blockers, calcium channel blockers and diuretics offer limited and varying relief of symptoms. They may help with function but may also have adverse side effects. A range of surgical and nonsurgical procedures can be used to treat HCM: Septal myectomy- Septal myectomy is open-heart surgery. Alcohol septal ablation (nonsurgical procedure) - In this procedure, ethanol (a type of alcohol) is injected through a tube into the small artery that supplies blood to the area of heart muscle thickened by HCM. Surgically implanted devices – Surgeons can implant several types of devices to help the heart work better, including: Implantable cardioverter defibrillator (ICD), Pacemaker, Cardiac resynchronization therapy (CRT) device. Heart transplant – In HCM patients with advanced, end-stage disease, a heart transplant may be considered. In this procedure, a person’s diseased heart is replaced with a healthy donor heart.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hypertrophic cardiomyopathy R&D. The therapies under development are focused on novel approaches for Hypertrophic cardiomyopathy.
This segment of the Hypertrophic cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertrophic cardiomyopathy Emerging Drugs
- Mavacamten: MyoKardia
In May, 2021, Bristol Myers Squibb announced that data from multiple studies across the company’s clinical program investigating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) will be presented at the upcoming American College of Cardiology’s 70th Annual Scientific Session (ACC.21).
- IMB-1018972: Imbria pharmaceticals
It is currently in Phase II stage of development for Hypertrophic cardiomyopathy and is being developed by Imbria pharmaceticals.
Further product details are provided in the report..
Hypertrophic cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Hypertrophic cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Hypertrophic cardiomyopathy
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Hypertrophic cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypertrophic cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertrophic cardiomyopathy drugs.
Hypertrophic cardiomyopathy Report Insights
- Hypertrophic cardiomyopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Hypertrophic cardiomyopathy drugs?
- How many Hypertrophic cardiomyopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Hypertrophic cardiomyopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertrophic cardiomyopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hypertrophic cardiomyopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Imbria pharmaceticals
- Cytokinetics
- MyoKardia
- Celltrion
- Tenaya Therapeutics
- IMB-1018972
- CK-3773274
- Mavacamten
- CT-G20
Introduction
Executive Summary
Hypertrophic cardiomyopathy: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypertrophic cardiomyopathy– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hypertrophic cardiomyopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hypertrophic cardiomyopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Mavacamten: MyoKardia
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101: Imbria pharmaceticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
CT-G20: Celltrion
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Hypertrophic cardiomyopathy Key Companies
Hypertrophic cardiomyopathy Key Products
Hypertrophic cardiomyopathy- Unmet Needs
Hypertrophic cardiomyopathy- Market Drivers and Barriers
Hypertrophic cardiomyopathy- Future Perspectives and Conclusion
Hypertrophic cardiomyopathy Analyst Views
Hypertrophic cardiomyopathy Key Companies
Appendix
Executive Summary
Hypertrophic cardiomyopathy: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypertrophic cardiomyopathy– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hypertrophic cardiomyopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hypertrophic cardiomyopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Mavacamten: MyoKardia
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101: Imbria pharmaceticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
CT-G20: Celltrion
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Hypertrophic cardiomyopathy Key Companies
Hypertrophic cardiomyopathy Key Products
Hypertrophic cardiomyopathy- Unmet Needs
Hypertrophic cardiomyopathy- Market Drivers and Barriers
Hypertrophic cardiomyopathy- Future Perspectives and Conclusion
Hypertrophic cardiomyopathy Analyst Views
Hypertrophic cardiomyopathy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hypertrophic cardiomyopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hypertrophic cardiomyopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hypertrophic cardiomyopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hypertrophic cardiomyopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
